- 106 Downloads
Levofloxacin, the optically pure levorotatory isomer of ofloxacin, is a fluoro-quinolone antibacterial agent. Like other fluoroquinolones, it acts on bacterial topoisomerase and has activity against a broad range of Gram-positive and Gram-negative organisms. Levofloxacin also appears to have improved activity against Streptococcus pneumoniae compared with ciprofloxacin or ofloxacin. Levofloxacin distributes well and achieves high levels in excess of plasma concentrations in many tissues (e.g. lung, skin, prostate). High oral bioavailability allows switching from intravenous to oral therapy without dosage adjustment.
In patients with mild to severe community-acquired pneumonia receiving treatment for 7 to 14 days, oral levofloxacin was similar in efficacy to amoxicillin/clavulanic acid, and intravenous and/or oral levofloxacin was superior to intravenous ceftriaxone and/or oral cefuroxime axetil. With levofloxacin use, clinical success (clinical cure or improvement) rates were 87 to 96% and bacteriological eradication rates were 87 to 100%. In the 5-to 10-day treatment of acute exacerbations of chronic bronchitis, oral levofloxacin was similar in efficacy to oral cefuroxime axetil or cefaclor. Levofloxacin resulted in clinical success in 78 to 94.6% of patients and bacteriological eradication in 77 to 97%. Oral levofloxacin was also similar in efficacy to amoxicillin/clavulanic acid or oral clarithromycin in patients with acute maxillary sinusitis treated for 7 to 14 days.
Equivalence between 7-to 10-day therapy with oral levofloxacin and ciprofloxacin was seen in patients with uncomplicated skin and soft tissue infections. Clinical success was seen in 97.8 and 96.1% of levofloxacin recipients and bacteriological eradication in 97.5 and 93.2%. Complicated urinary tract infections, including pyelonephritis, responded similarly well to oral levofloxacin or ciprofloxacin for 10 days or lomefloxacin for 14 days. Clinical success and bacteriological eradication rates with levofloxacin occurred in 92 to 93.3% and 93.6 to 94.7% of patients.
Conclusions: Levofloxacin can be administered in a once-daily regimen as an alternative to other fluoroquinolones in the treatment of infections of the urinary tract, skin and soft tissues. Its more interesting use is as an alternative to established treatments of respiratory tract infections. S. pneumoniae appears to be more susceptible to levofloxacin than to ciprofloxacin or ofloxacin. Other newer fluoroquinolone agents that also have enhanced in vitro antipneumococcal activity may not share the well established tolerability profile of levofloxacin, which also appears to improve on that of some older fluoroquinolones.
Levofloxacin has a broad range of activity against Gram-positive and Gram-negative, atypical and intracellular bacteria and is moderately active against anaerobes.
Methicillin-or oxacillin-susceptible staphylococci (including Staphylococcus aureus, S. saprophyticus and S. epidermidis) are also susceptible to levofloxacin. Levofloxacin is similar in activity against methicillin-or oxacillin-susceptible S. epidermidis to ofloxacin or ciprofloxacin, but less active against these strains than sparfloxacin or trovafloxacin. However, staphylococci that were resistant to methicillin or oxacillin were also resistant to levofloxacin, ciprofloxacin, ofloxacin and sparfloxacin.
Streptococcus pneumoniae that were susceptible, intermediately susceptible or resistant to penicillin and S. pyogenes were all susceptible to levofloxacin. When evaluated on the basis of a 2-dilution difference between agents, the inhibitory activity of levofloxacin against S. pneumoniae appeared to be similar to that of ofloxacin, ciprofloxacin and sparfloxacin, but less than that of trovafloxacin. However, at optimum bactericidal concentrations, levofloxacin is more active against S. pneumoniae than ofloxacin, ciprofloxacin or sparfloxacin. Further, S. pneumoniae strains had minimum inhibitory concentrations below National Committee for Clinical Laboratory Standards recommended susceptibility breakpoints for levofloxacin but not for ofloxacin.
Most enterococci and Enterobacteriaceae were susceptible to levofloxacin, including Enterococcus faecalis, Citrobacter freundii, C. diversus, Enterobacter aerogenes, E. cloacae, Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Morganella morganii, Proteus mirabilis and P. vulgaris. However, Providencia stuartii and P. rettgeri were resistant or had intermediate susceptibility; most Serratia spp. were only intermediately susceptible. E.coli and K. pneumoniae with cephalosporin resistance were also resistant to levofloxacin. Resistance of these organisms to other fluoroquinolones tested was also evident.
P. aeruginosa is only moderately susceptible to levofloxacin or other fluoroquinolones, and nonpseudomonas nonfermenters also do not appear to be susceptible to levofloxacin. Anaerobes vary in susceptibility to levofloxacin, with Bacteroides fragilis strains ranging from susceptible to resistant, although Clos-tridium perfringens is susceptible. In contrast, Gram-negative bacteria, such as Haemophilus influenzae, Moraxella catarrhalis and Legionella pneumophila, and ‘atypical’ pathogens, such as Mycoplasma pneumoniae and Chlamydia pneumoniae, are susceptible to levofloxacin and other fluoroquinolones.
Oral levofloxacin is 100% systemically available and its bioavailability is not affected by meals. Intravenous or oral routes of administration may be used interchangeably. The drug has linear pharmacokinetics over 50 to 1000mg doses. Steady state is reached after ≈3 days; the elimination half-life is 6.8 to 8.9 hours. ≈80% of a dose is found in the urine as unchanged drug and ≤5% as inactive N-oxide and demethyl metabolites within 24 hours. The active drug distributes well to target body tissues and fluids in the respiratory tract, skin, urine and prostate and its uptake by cells makes it suitable for use against intracellular pathogens. Dosages should be reduced in patients with renal failure, in whom levofloxacin elimination is decreased. Old age and gender do not affect levofloxacin pharmacokinetics.
Published and unpublished studies support the use of levofloxacin in patients with community-acquired pneumonia (CAP), acute maxillary sinusitis, acute exacerbations of chronic bronchitis (AECB), uncomplicated skin and soft tissue infections (SSTIs) or complicated urinary tract infections (UTIs, including acute pyelonephritis). Its efficacy has been demonstrated in a small number of comparative studies in each of these indications, supplemented by noncomparative trials in some indications. A total of >5600 patients in these trials were evaluated on at least 1 of the major outcome indicators: clinical cure rate, clinical success rate (clinical cure or improvement) and bacteriological eradication rate.
In patients with mild to severe CAP, oral levofloxacin 500 mg/day produced a similar clinical success rate (95.2%) to that seen with amoxicillin/clavulanic acid 1500/375 mg/day (95.3%) when these regimens were administered for 7 to 10 days in a double-blind study. In contrast, intravenous or oral levofloxacin 500 mg/day resulted in a statistically superior clinical success rate (96%) to that seen with the combined results of intravenous ceftriaxone 1 or 2 g/day or oral cefur-oxime axetil 1000 mg/day (90%) after 7 to 14 days' treatment of patients with mild to severe CAP in a single-blind study. Patients with moderate to severe CAP achieved clinical cure and success rates of 65 and 87% after levofloxacin 500mg twice daily orally or intravenously and 55 and 86% after intravenous ceftriaxone 4000mg once daily. Bacteriological eradication was seen in 87 to 100% of patients receiving levofloxacin and in similar proportions of those receiving comparator agents (amoxicillin/clavulanic acid 97.5%; ceftriaxone and/or cefuroxime axetil 87%).
In AECB, oral levofloxacin 250 or 500mg once daily for 7 to 10 days was similar in efficacy to oral cefuroxime axetil 250mg twice daily for the same duration. Levofloxacin 500mg once daily was also equivalent in efficacy to cefuroxime axetil 250mg twice daily or cefaclor 250mg 3 times daily when given in shorter courses than its comparators (5 to 7 days vs 10 or 7 to 10 days). Clinical success and bacteriological eradication rates were similar between patients receiving levofloxacin (78 to 94.6% and 77 to 97%, respectively) and those receiving cefuroxime axetil (66 and 92.6%, and 68 and 95%, respectively) or cefaclor (92 and 87%, respectively).
When used for 10 to 14 days to treat radiologically confirmed acute maxillary sinusitis, oral levofloxacin 500mg once daily was similar in efficacy to oral amoxicillin/clavulanic acid 500mg/125mg 3 times daily or oral clarithromycin 500mg twice daily. Clinical cure rates with levofloxacin ranged from 58.3 to 63.2% (and were similar to that for amoxicillin/clavulanic acid, 58.6%). Bacteriological eradication rates in 2 noncomparative trials were 88.6 and 92%. Levofloxacin clinical success rates of 88.3 to 96% were also similar to those of amoxicillin/clavulanic acid (87.3%) and clarithromycin (93.3%).
When per-pathogen eradication rates were examined for respiratory pathogens detected in clinical trials, eradication rates with levofloxacin against S. aureus, M. catarrhalis, E. coli, H. influenzae, H. parainfluenzae, K. pneumoniae, C. pneumoniae, M. pneumoniae and L. pneumophila were very good to excellent and ranged from 89.1 to 100%. A lower eradication rate was seen for levofloxacin against P. aeruginosa (63%).
In patients with uncomplicated skin and soft tissue infections, oral levofloxaein 500mg once daily for 7 to 10 days was similar in efficacy to oral ciprofloxacin 500mg twice daily. Clinical success occurred in 96.1 and 97.8% of levofloxacin recipients and 93.5 and 94.3% of ciprofloxacin recipients, whereas bacteriological eradication rates were 93.2 and 97.5% for levofloxacin and 88.8 and 91.7% for ciprofloxacin. Comparisons between levofloxacin and either ciprofloxacin or lomefloxacin in patients with complicated urinary tract infections also resulted in similar efficacy between these groups. Levofloxacin 250 mg/day for 10 days produced clinical success in 92 and 92.9% of patients and bacteriological eradications in 93.6 and 95.3%. The clinical success rates were 88% after ciprofloxacin 250mg twice daily for 10 days and 88.5% after lomefloxacin 400mg once daily for 14 days; bacteriological eradication rates were 97.5 and 92.1%, respectively.
Adverse events associated with levofloxacin are usually transient, mild to moderate in severity and generally similar to that of other fluoroquinolone agents. Nausea (1.1 to 3%) and diarrhoea (1.1. to 2.89%), are among the more common events seen after oral or intravenous use of the drug in clinical trials. Phlebitis and reddening at the infusion site may also occur with intravenous levofloxacin. According to an overview, the overall incidence of drug-related adverse events appears to be lower with levofloxacin (3.3%) than with the other fluoroquinolones ofloxacin (4.3%), ciprofloxacin (5.5 to 10.2%) or pefloxacin (8%).
Serious adverse events include rare cases of pseudomembranous colitis and haemolytic anaemia. The safety and efficacy of levofloxacin in children and adolescents below the age of 18 years have not been established. Fluoroquinolones, including levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species. Photosensitisation with levofloxacin is similar in incidence to that seen with ofloxacin and ciprofloxacin. CNS events such as seizures may be related to concurrent use of theophylline or nonsteroidal anti-inflammatory drugs and may occur less frequently with levofloxacin than ofloxacin.
Sucralfate and antacids that contain di-or trivalent cations may chelate with levofloxacin and thus limit its absorption. Cimetidine and probenecid may compete with levofloxacin for renal tubular secretion and thus prolong the half-life of levofloxacin. Both hyper-and hypoglycaemia have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent.
Dosage and Administration
Levofloxacin may be used to treat acute maxillary sinusitis, AECB, CAP, SSTIs or complicated UTIs (including pyelonephritis). The drug is available in both oral and intravenous dosage forms. European and US dosage guidelines for levofloxacin differ.
In the US, levofloxacin may be administered orally or intravenously for all indications. The usual dose of 500mg once daily may be used for acute sinusitis (administered for 10 to 14 days), AECB (7 days), CAP (7 to 14 days) and uncomplicated SSTIs (7 to 10 days). Levofloxacin 250mg once daily should be administered for 10 days to treat complicated UTIs or pyelonephritis.
In Europe, oral levofloxacin 500mg once daily is used to treat sinusitis (duration 10 to 14 days) and 250 to 500mg once daily is used for AECB (7 to 10 days). In patients with CAP, intravenous or oral levofloxacin 500mg once or twice daily is administered for 7 to 14 days. Levofloxacin 250mg once daily orally or intravenously may be used for 7 to 10 days in patients with complicated UTIs or pyelonephritis, but higher intravenous dosages may be considered for patients with severe disease. A 250mg once-daily or 500mg once-or twice-daily dosage of oral levofloxacin may be administered for 7 to 14 days for SSTIs; if intravenous levofloxacin is used, 500mg twice daily is recommended.
Use of levofloxacin is contraindicated in children, adolescents, pregnant or breastfeeding women, and patients with epilepsy or a history of tendon disorders related to fluoroquinolones. Caution is warranted when patients with renal impairment receive levofloxacin concomitantly with probenecid or cimetidine; levofloxacin dosages should be adjusted according to creatinine clearance. Administration of sucralfate, iron salts or antacids containing magnesium or aluminium should be separated from levofloxacin administration by 2 hours.
KeywordsOfloxacin Levofloxacin Antimicrob Agent Eradication Rate Sparfloxacin
Unable to display preview. Download preview PDF.
- 9.Goldstein EJC, Nesbit CA, Citron DM. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, spar-floxacin, and 11 other oral antimicrobial agents against 194 aerobics and anaerobic bite wound isolates. Antimicrob Agents Chemother 1995 May; 39: 1097–100PubMedCrossRefGoogle Scholar
- 15.Hoogkamp-Korstanje JAA. In. vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother 1997 Sep; 40: 427–31PubMedCrossRefGoogle Scholar
- 17.Casellas JM, Gilardoni M, Tomè G, et al. Comparative in vitro activity of levofloxacin against isolates from adult patients with community-acquired lower respiratory tract infections [abstract no. P1148]. 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne; 1997 May 25–8Google Scholar
- 18.Felmingham D, Robbins M, Mathias I, et al. AEuropean multicentre study of the comparative in vitro susceptibility of Gram-positive bacteria to levofloxacin [abstract no. P018]. 20th International Congress of Chemotherapy; 1997 Jun 29; 94Google Scholar
- 22.Klugman KP, Capper T, Bryskier A. In vitro susceptibility of penicillin-resistant Streptococcus pn.eumon.iae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 1996 Dec; 40: 2802–4PubMedGoogle Scholar
- 24.Fremaux A, Sissla G, Geslin P. In. vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pn.eumon.iae [abstract no. P1147]. 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland. 1997 May 25–8Google Scholar
- 25.Reinert R, Lütticken R, Lemperle M, et al. Comparative in. vitro activity of ofloxacin, levofloxacin, D (−)ofloxacin, ciprofloxacin, amoxicillin, cefpodoxime, cefixime, cefuroxime, faropenem, erythromycin and tetracycline against S. pneu-moniae [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29; 92–3Google Scholar
- 30.Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995 Jan; 35: 230–2PubMedCrossRefGoogle Scholar
- 32.Georgopoulos A, Moser C, Buxbaum A, et al. Antipneumococcal activity of Bay 12-8039 and trovofloxacin in comparison to older quinolones [abstract]. 20th International Congress of Chemotherapy; 1997 Jun 29; 80Google Scholar
- 35.Keller N, Smollen G, Davidson Y, et al. The sensitivity of Streptococcus pn.eumon.iae to levofloxacin and other antibiotic drugs [abstract no. P018]. 20th International Congress of Chemotherapy; 1997 Jun 29; 94Google Scholar
- 36.Thomson K, Chartrand S, Sanders C, et al. Activity of levofloxacin and 12 comparison agents against pediatric isolates of Streptococcus pneumoniae with varying levels of penicillin resistance [abstract]. 20th International Congress of Chemotherapy 1997 Jun 29: 92Google Scholar
- 38.Soussy CJ, Cluzel M, Ploy MC, et al. In. vitro antibacterial activity of a new fluoroquinolone, levofloxacin, against hospital isolates: a multicentre study [abstract no. P405]. 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne, Switzerland. May 25–8, 1997Google Scholar
- 40.Felmingham D, Robbin MJ, Mathias I, et al. Results of a European multicentre study of the comparative in. vitro susceptibility of Gram-negative bacteria to levofloxacin [abstract no. P1150]. 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne; 1997 May 25–8Google Scholar
- 43.Visalli M, Bajaksouzian S, Jacobs M, et al. Synergy between levofloxacin and 4 drags against Pseudomonas aeruginosa [abstract no E145]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28: 140Google Scholar
- 44.Visalli M, Spangler SK, Jacobs M, et al. Activity of levofloxacin compared to 9 drags against non-fermenters [abstract no. P018]. 20th International Congress of Chemotherapy; Sydney; 1997 Jun 29–Jul 3Google Scholar
- 45.Kitzis MD, Goldstein FW, Miegi M, et al. In. vitro activity of levofloxacin, a new fluoroquinolone: evaluation on H. influenzcie and M. catarrhalis [abstract no. P408]. 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne; 1997 May 25–8Google Scholar
- 51.NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically —4h ed; Approved Standard. NCCLS Document M7-A4 (ISBN 1-56238-309-4). NCCLS, 940 West Valley Road, Suite 1400, Wayne Pennsylvania, 19087, USAGoogle Scholar
- 53.Kitzis MD, Goldstein FW, Acar JF. Selection of one step resistant mutants of S. pn.eumon.iae (SP) by levofloxacin comparatively to other fluoroquinolones (FQ) [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17; 62Google Scholar
- 54.Sulavik M, Peshick S, Barg N. Ciprofloxacin (CIP) selects low-level quinolone-resistant mutants (LLQR) of meth-resistant (MR) and -susceptible (MS) Staphylococcus aureus (SA) more frequently than ofloxacin (OFX) or levofloxacin (LFX) in. vitro and in. vivo [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15; 54Google Scholar
- 58.Zeller V, Fourgeaud M, Moreau NJ. Accumulation of fluoroquinolones by Streptococcus pneumoniae and resistance arising from active fluoroquinolone efflux [abstract no. C57]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto; 1997 Sep 28–Oct 1Google Scholar
- 60.Raddatz JK, Ostergaard BE, Hovde LB, et al. An in vitro pharmacodynamic (PD) evaluation of levofloxacin (L) against a TEM-10 producing Klebsiella pn.eumon.iae (KP) isolate and two strains of P seudornonus aeruginosa (PA) [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15; 13Google Scholar
- 61.Markus A, Isert D, Kiesel N, et al. Killing activity of levofloxacin (LEF) and ciprofloxacin (CIP) against Streptococcus pn.eumon.iae in. vitro and in. vivo [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17; 90Google Scholar
- 62.Odenholt I, Löwdin E, Cars O. Killing effect of levofloxacin compared to that of ciprofloxacin and sparfloxacin [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15; 82Google Scholar
- 66.Pendland SL, Danziger LH. The postantibiotic effect of levofloxacin on Bacteroides species [abstract]. Clin Infect Dis 1995 Sep; 21: 748Google Scholar
- 75.Ortho Pharmaceutical Corporation and McNeil Pharmaceutical. Once-a-day LevaquinTM (levofloxacin) tablets/injection. Product information. Raritan, NJ, USA 09969-0602Google Scholar
- 76.Ortho-McNeil Pharmaceuticals. 1998 Data on file. Raritan, NJGoogle Scholar
- 77.Guay DRP. Pharmacokinetics and pharmacodynamics of ofloxacin in urinary tract infections. In: Penetration: international update on ofloxacin and levofloxacin. Tokyo: Biomedis, 1997: 26–33Google Scholar
- 82.Labro MT, Vazifeh D, Bryskier A. Levofloxacin uptake by human polymorphonuclear neutrophils in vitro [abstract]. 20th International Congress of Chemotherapy 1997 Jun 29: 97Google Scholar
- 83.Vazifeh D, Bryskier A, Labro MT. Investigation of the mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils [abstract no. A74]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto; 1997 Sep 28–Oct 1Google Scholar
- 84.Honeybourne D, Andrews JM, Jevons G, et al. Penetration of levofloxacin (HR355) into lung tissues after a single 500mg oral dose [abstract no. P377]. 8th European Congress of Clinical Microbiology and Infectious Diseases; Lausanne, Switzerland. 1997 May 25–8Google Scholar
- 85.Gisclon LG, Curtin CR, Chien SC, et al. The pharmacokinetics (PK) of levofloxacin (LVFX) in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15; 3Google Scholar
- 88.File JTM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997 Sep; 41: 1965–72PubMedGoogle Scholar
- 89.Carbon C, Members of the International Study Group. Comparative study of levofloxacin and co-amoxiclav in the treatment of community-acquired pneumonia in adults [abstract no. LM70]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto; 1997 Sep 28–Oct 1Google Scholar
- 90.Carbon C, Zeimen M, Rangaraj M, et al. Evaluation of the efficacy and safety of oral levofloxacin 500 mg once daily vs 500 mg twice daily vs amoxicillin/clavulanic acid 500/125 thrice daily for 7 to 10 days in the treatment of community-acquired pneumonia in adults: a double-blind, double-dummy, multinational, multicentre, comparative study. Hoechst Marion Roussel, (data on file)Google Scholar
- 91.Norrby RS, Petermann W, Willcox PA, et al. Levofloxacin versus ceftriaxone in the treatment of pneumonia in hospitalised patients [abstract no T108]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 62Google Scholar
- 92.Hoechst Marion Roussel. Open, controlled, randomised, multinational, comparative study of the efficacy, safety and tolerance of levofloxacin (HR355) versus ceftriaxone in the treatment of hospitalised patients with pneumonia. HR335/2/MN/301/LR. Data on file, Hoechst AG, Frankfurt am Main, GermanyGoogle Scholar
- 93.RW Johnson Pharmaceutical Research Institute. Statistical review of pneumonia study M92-075. Data on fileGoogle Scholar
- 94.RW Johnson Pharmaceutical Research Institute. Statistical review of pneumonia study K90-071. Data on fileGoogle Scholar
- 95.DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997; 42(2): 206–13Google Scholar
- 97.Shah PM, Members of the International Study Group. Levofloxacin versus cefuroxime axetil in the treatment of acute axacerbations of chronic bronchitis [abstract no. LM38]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 1997 Sep 28–Oct 1Google Scholar
- 98.Adelglass J, DeAbate CA, McElvaine P, et al. A comparison of levofloxacin (LVFX) QD and amoxicillin-clavulanate (Amox/Clav) TID for the treatment of acute bacterial sinusitis [abstract no 290]. Clin Infect Dis 1996 Oct; 23: 913Google Scholar
- 99.Kahn JB, Rielly-Gauvin K, Demartin EL, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of oral levofloxacin and BIAXIN (Rm) in the treatment of acute maxillary sinusitis in adults [abstract no 579]. Clin Infect Dis 1997 Aug; 25: 462Google Scholar
- 100.Gehanno P, French Sinusitis Study Group. Oral levofloxacin, 500 mg once daily, in the treatment of acute maxillary sinusitis [abstract no T106]. Antiinfect Drugs Chemother 1998; 16 Suppl. 1: 62Google Scholar
- 101.Gehanno P, Rangaraj M, Lebrun MJ, et al. Once daily 500 mg oral levofloxacin in the treatment of acute maxillary sinusitis. Study no. F/93/355/01. Hoechst-Roussel, France. Data on file, 1998Google Scholar
- 106.Richard GA, Childs S, Fowler C, et al. A comparison of levofloxacin (LVFX) and ciprofloxacin (cipro) for the treatment of complicated urinary tract infections (cUTI) [abstract]. Clin Infect Dis 1996 Oct; 23: 914Google Scholar
- 107.Richard GA, Klimberg IN, Fowler C, et al. A combined analysis of two studies comparing levofloxacin (LVFX) with two other fluoroquinolones for the treatment of acute pyelonephritis (pyelo) [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996 Sep 15: 281Google Scholar
- 108.Hoechst Marion Roussel. Summary of product specifications; Tavanic 250 mg tablet, Tavanic 500 mg tablet, Tavanic i.V. 500 mg. Data on fileGoogle Scholar
- 112.Boccumini L, Fowler C, Campbell T, et al. Photoreaction potential (PR) of orally administered levofloxacin (LVFX) in healthy subjects [abstract]. Clin Infect Dis 1996 Oct; 23: 913Google Scholar
- 113.Kohno K, Nozaki M, Takeda N, et al. Neuroexcitable effects of levofloxacin, a novel quinolone antibacterial, in concomitant use of non-steroidal anti-inflammatory drugs: the comparative study with other quinolones [in Japanese]. Yakuri to Chiryo 1994 Apr; 22: 1811–21Google Scholar
- 118.OkimotoN, Niki Y, Soejima R. Effect of Levofloxacin on serum concentration of theophylline [in Japanese]. Chemotherapy 1992 May; 40(S-3): 68–74Google Scholar
- 120.Gaitonde MD, Mendes P, House ESA, et al. The effects of cimetidine and probenecid on the pharmacokinetics of levofloxacin (LVFX) [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Sep 17: 8Google Scholar
- 124.Anonymous. The choice of antibacterial drugs. Med Lett Drugs Ther 1998 Mar 27; 40(1023): 33–42Google Scholar
- 125.Bartlett JG, Breiman RF, Mandell LA, et al. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811–38Google Scholar